share_log

Bellerophon Therapeutics | SC 13G: Statement of acquisition of beneficial ownership by individuals-Janus Henderson Group plc(5.1%),Janus Henderson Biotech Innovation Master Fund Ltd(5.1%)

SEC announcement ·  May 25, 2023 11:17
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more